Clinical Trials Logo

Dysosmia clinical trials

View clinical trials related to Dysosmia.

Filter by:
  • None
  • Page 1

NCT ID: NCT04964414 Terminated - Covid19 Clinical Trials

Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19

Start date: September 30, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This research study is a randomized controlled trial in pediatric and young adult patients who have lost their sense of smell due to COVID-19 viral infection. The goals are: 1. to learn more about the effects of smell retraining therapy on smell loss following COVID-19 and 2. to determine if budesonide-saline irrigations make smell retraining therapy more effective.

NCT ID: NCT04661800 Not yet recruiting - Amyloidosis Clinical Trials

Study of Olfactory Disorders in Patients With Cardiac Amyloidosis

AMYLODOR
Start date: March 19, 2021
Phase: N/A
Study type: Interventional

Amyloidosis is a disease caused by the continuous accumulation of fibrillary proteins in the extracellular matrix causing the architecture of different organs to be disrupted. The prevalence of the disease increases with age. The two most common forms are light chain amyloidosis (AL) and transthyretin (TTR). TTR amyloidosis may be hereditary (m-TTR, or mutated) or age-related (WT-TTR, or wild). The latter is also called senile amyloidosis. In all these forms, cardiac impairment is common and leads the patient to consult/or be referred to a cardiological center unfortunately often too late when the prognosis is directly related to the severity of the heart attack. The description/discovery of clinical signs prior to heart disease is important to improve the detection and diagnosis of early forms of cardiac amyloidosis (CA). For example, an infiltration of the carpal tunnel synovial by amyloid deposits is observed in some patients, 5 years before the onset of signs of heart failure and is the only warning sign of the disease known to date. We also showed in a previous study that patients had more severe and earlier impairment of hearing function than expected by age and gender. Objective The main objective is to define the prevalence and severity of smell and taste disorders in a population of patients with cardiac amyloidosis (3 types of mutated or wild AL amyloidosis and TTR). The main endpoint is to determine the number of patients with impaired smell and taste's functions in a population of patients diagnosed with cardiac amyloidosis (3 types of mutated (hereditary) or senile wild amyloidosis (3 types of AL amyloidosis and TTR). Method Successive monocentric cross-sectional study on the screening of smell and taste disorders carried out as part of a cardiology hospitalization programmed for the cardiology follow-up of his pathology in a population of patients diagnosed with AC.